Total Payments
$3,462
2024 Payments
$266.94
Companies
25
Transactions
199
Medicare Patients
9,711
Medicare Billing
$1.8M
Payment Breakdown by Category
Food & Beverage$2,974 (85.9%)
Travel$474.22 (13.7%)
Education$13.89 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,974 | 196 | 85.9% |
| Travel and Lodging | $474.22 | 2 | 13.7% |
| Education | $13.89 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,018 | 60 | $0 (2024) |
| Cook Incorporated | $474.22 | 2 | $0 (2019) |
| Novo Nordisk Inc | $345.06 | 25 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $272.52 | 19 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $208.65 | 15 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $137.30 | 11 | $0 (2022) |
| PFIZER INC. | $124.55 | 9 | $0 (2024) |
| Lilly USA, LLC | $102.23 | 7 | $0 (2019) |
| Astellas Pharma US Inc | $97.10 | 7 | $0 (2024) |
| ABBVIE INC. | $87.33 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $266.94 | 18 | AstraZeneca Pharmaceuticals LP ($62.42) |
| 2023 | $351.37 | 17 | AstraZeneca Pharmaceuticals LP ($182.03) |
| 2022 | $419.07 | 27 | AstraZeneca Pharmaceuticals LP ($117.61) |
| 2021 | $429.31 | 31 | AstraZeneca Pharmaceuticals LP ($145.73) |
| 2020 | $171.15 | 13 | AstraZeneca Pharmaceuticals LP ($50.83) |
| 2019 | $1,027 | 42 | Cook Incorporated ($474.22) |
| 2018 | $535.89 | 35 | AstraZeneca Pharmaceuticals LP ($182.05) |
| 2017 | $260.65 | 16 | AstraZeneca Pharmaceuticals LP ($89.32) |
All Payment Transactions
199 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Cardio-renal | ||||||
| 11/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Obesity | ||||||
| 10/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: PSYCHIATRY | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: NEUROSCIENCE | ||||||
| 08/22/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/15/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/01/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Diabetes | ||||||
| 07/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/20/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/06/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Obesity | ||||||
| 05/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/10/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: NEUROSCIENCE | ||||||
| 05/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: Diabetes | ||||||
| 02/08/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: NEUROSCIENCE | ||||||
| 01/03/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: Biological | ||||||
| 12/21/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: Diabetes | ||||||
| 11/09/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Diabetes | ||||||
| 10/26/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: Inflammation | ||||||
| 09/28/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.04 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/21/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Diabetes | ||||||
| 09/07/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: Biological | ||||||
| 08/03/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,251 | 5,426 | $742,720 | $433,490 |
| 2022 | 24 | 2,828 | 7,130 | $951,015 | $520,705 |
| 2021 | 25 | 2,470 | 5,677 | $732,940 | $420,788 |
| 2020 | 21 | 2,162 | 5,495 | $694,870 | $388,325 |
Total Patients
9,711
Total Services
23,728
Medicare Billing
$1.8M
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 347 | 1,269 | $158,625 | $87,495 | 55.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 370 | 474 | $118,525 | $71,242 | 60.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 229 | 813 | $101,625 | $61,098 | 60.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 399 | 523 | $104,625 | $52,618 | 50.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 184 | 403 | $60,525 | $41,074 | 67.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 165 | 236 | $35,400 | $23,416 | 66.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 69 | 392 | $39,200 | $21,312 | 54.4% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 54 | 62 | $18,600 | $14,738 | 79.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 62 | 312 | $23,385 | $13,117 | 56.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 70 | 276 | $23,460 | $11,962 | 51.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 59 | 59 | $11,800 | $8,583 | 72.7% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 12 | 111 | $11,100 | $5,276 | 47.5% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 12 | 111 | $8,325 | $4,891 | 58.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 28 | 30 | $6,000 | $3,414 | 56.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $4,250 | $3,336 | 78.5% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 11 | 91 | $5,915 | $3,217 | 54.4% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 13 | 23 | $2,530 | $2,029 | 80.2% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 15 | 23 | $2,300 | $1,514 | 65.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 13 | 13 | $1,950 | $925.34 | 47.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 40 | 73 | $2,555 | $873.67 | 34.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 23 | 23 | $805.00 | $781.31 | 97.1% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 23 | 23 | $805.00 | $503.70 | 62.6% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 36 | 69 | $415.00 | $75.00 | 18.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 500 | 2,063 | $257,875 | $125,926 | 48.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 419 | 548 | $137,000 | $92,586 | 67.6% |
About Dr. Samir Patel, MD
Dr. Samir Patel, MD is a Internal Medicine healthcare provider based in Spotswood, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1588659296.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samir Patel, MD has received a total of $3,462 in payments from pharmaceutical and medical device companies, with $266.94 received in 2024. These payments were reported across 199 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($2,974).
As a Medicare-enrolled provider, Patel has provided services to 9,711 Medicare beneficiaries, totaling 23,728 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Spotswood, NJ
- Active Since 09/19/2005
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1588659296
Products in Payments
- FARXIGA (Drug) $734.02
- Cook Medical CBDE (Device) $474.22
- XARELTO (Drug) $235.58
- ENTRESTO (Drug) $179.59
- JARDIANCE (Drug) $176.64
- BREZTRI (Drug) $168.55
- Ozempic (Drug) $151.65
- ELIQUIS (Drug) $83.92
- Rybelsus (Drug) $78.32
- LOKELMA (Drug) $77.80
- Oxford (Device) $73.94
- Kerendia (Drug) $58.12
- MYRBETRIQ (Drug) $54.92
- UBRELVY (Drug) $54.62
- SPINEJACK (Device) $44.43
- Vascepa (Drug) $42.42
- TOUJEO (Drug) $41.02
- JANUVIA (Drug) $39.27
- Victoza (Drug) $38.53
- BEVESPI AEROSPHERE (Drug) $38.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.